The assembly of neutrophil inflammasomes during COVID-19 is mediated by type I interferons.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 08 02 2024
accepted: 24 06 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 22 8 2024
Statut: epublish

Résumé

The severity of COVID-19 is linked to excessive inflammation. Neutrophils represent a critical arm of the innate immune response and are major mediators of inflammation, but their role in COVID-19 pathophysiology remains poorly understood. We conducted transcriptomic profiling of neutrophils obtained from patients with mild and severe COVID-19, as well as from SARS-CoV-2 infected mice, in comparison to non-infected healthy controls. In addition, we investigated the inflammasome formation potential in neutrophils from patients and mice upon SARS-CoV-2 infection. Transcriptomic analysis of polymorphonuclear cells (PMNs), consisting mainly of mature neutrophils, revealed a striking type I interferon (IFN-I) gene signature in severe COVID-19 patients, contrasting with mild COVID-19 and healthy controls. Notably, low-density granulocytes (LDGs) from severe COVID-19 patients exhibited an immature neutrophil phenotype and lacked this IFN-I signature. Moreover, PMNs from severe COVID-19 patients showed heightened nigericin-induced caspase1 activation, but reduced responsiveness to exogenous inflammasome priming. Furthermore, IFN-I emerged as a priming stimulus for neutrophil inflammasomes. These findings suggest a potential role for neutrophil inflammasomes in driving inflammation during severe COVID-19. Altogether, these findings open promising avenues for targeted therapeutic interventions to mitigate the pathological processes associated with the disease.

Identifiants

pubmed: 39172744
doi: 10.1371/journal.ppat.1012368
pii: PPATHOGENS-D-24-00299
doi:

Substances chimiques

Interferon Type I 0
Inflammasomes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1012368

Informations de copyright

Copyright: © 2024 Cabrera et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Luz E Cabrera (LE)

Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.

Suvi T Jokiranta (ST)

Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland.
Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Sanna Mäki (S)

Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.

Simo Miettinen (S)

Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.
Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.

Ravi Kant (R)

Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.
Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Department of Tropical Parasitology, Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Gdynia, Poland.

Lauri Kareinen (L)

Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.
Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.

Tarja Sironen (T)

Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.
Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.

Jukka-Pekka Pietilä (JP)

Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Meilahti Vaccine Research Center MeVac, Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Anu Kantele (A)

Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Meilahti Vaccine Research Center MeVac, Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Eliisa Kekäläinen (E)

Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland.
Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Division of Virology and Immunology, HUSLAB Clinical Microbiology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.

Hanna Lindgren (H)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.

Pirkko Mattila (P)

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.

Anja Kipar (A)

Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.

Olli Vapalahti (O)

Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.
Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Division of Virology and Immunology, HUSLAB Clinical Microbiology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.

Tomas Strandin (T)

Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH